ABT · News · 20260821N
Diagnostic Market Demand
ABBOTT LABORATORIES · 2026-08-21 · Importance 17 · Surprise 24 · In source text
Abbott is seeing strong demand for cancer diagnostics, supporting growth in its Diagnostics business. The reported demand is attributed to increasing oncology screening activity and is expected to accelerate in the second half of 2026. Growth is being supported by Care-Gap programs, new patients and repeat screening volumes, with the Cologuard Plus rollout adding to the cancer-screening opportunity.
Key facts
- TD Cowen expects mid-teens franchise growth in Abbott's cancer diagnostics business and cited the upcoming Cologuard Plus rollout and Exact Sciences integration as contributors. source
- Abbott reported strong demand for cancer diagnostics as a primary reason for its Q2 outperformance. source
- TD Cowen raised its price target for Abbott Laboratories stock to $135 from $115, citing anticipated acceleration of the company's cancer diagnostics business. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | TD Cowen expects mid-teens franchise growth in Abbott's cancer diagnostics business and cited the upcoming Cologuard Plus rollout and… |